Investigating a new BCG vaccine strategy to prevent TB in children with HIV
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection
This study is testing a new version of the TB vaccine in young macaques to see if it can work better, especially for kids with HIV, by trying out different ways to give the vaccine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10891724 on NIH RePORTER |
What this research studies
This research focuses on improving the Bacillus Calmette-Guerin (BCG) vaccine, which is currently the only licensed vaccine for tuberculosis (TB). It aims to test a new, more attenuated strain of BCG, known as BCGΔ1419c, in young macaques that closely mimic the pediatric population. The study will explore different methods of vaccine delivery, including mucosal routes, to enhance the immune response in children, particularly those who are HIV-positive. Advanced techniques such as flow cytometry and RNA sequencing will be used to assess the vaccine's effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 1 to 2 years who are HIV-positive and at risk for tuberculosis.
Not a fit: Patients who are not HIV-positive or older than 2 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective TB vaccine for children, especially those living with HIV, significantly reducing their risk of developing the disease.
How similar studies have performed: Previous studies have shown promising results with alternative delivery methods of the BCG vaccine, indicating potential for success in this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Scanga, Charles a. — University of Pittsburgh at Pittsburgh
- Study coordinator: Scanga, Charles a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.